Guardant Health, Inc. GH

Guardant Health’s first-quarter filing shows revenue of $301.7 million but a net loss of $112.1 million, a deficit so wide the company’s operating income of negative $121.3 million looks less like a business and more like an expensive hobby. Cash burn from operations reached $65.6 million despite $989.3 million sitting on the balance sheet, a contradiction that suggests either the cash is trapped in a lab freezer or management is keeping it warm for a rainy day that never arrives. Shareholders’ equity sits at negative $181.1 million, which is the kind of arithmetic that usually prompts a polite knock on the door from the SEC rather than a quiet board discussion about R&D budgets. The company’s public website still chirps about “conquering cancer with data,” a slogan that collides awkwardly with a filing that reads like a startup’s first-year balance sheet with a PhD in oncology attached.

What Guardant actually sells are blood-based companion diagnostics and data services for oncology, built around tests like Guardant360 CDx that pair tumour mutations with approved therapies. The firm claims more than a million tests have been run by 12,000 doctors, a figure that sounds impressive until you notice the tests are largely reimbursed by Medicare and biopharma partners rather than paid for by jubilant patients. In March 2021, CMS granted advanced diagnostic laboratory test status to Guardant360 CDx, which locked in Medicare payment at the lowest available commercial rate from April 1, 2021, through December, a policy carrot that has yet to translate into consistent profitability. The company also offers GuardantINFORM data services and GuardantConnect referral services to biopharma clients, which diversifies revenue but also embeds Guardant deep inside the commercial incentives of drug developers rather than the straightforward world of patient diagnostics.

The latest 10-Q for the quarter ended March 31, 2026, lists revenue from contracts with customers (excluding assessed tax) at $301.7 million, net income attributable to the parent at negative $112.1 million, and operating income at negative $121.3 million. Cash and cash equivalents stand at $989.3 million, but net cash used in operating activities was $65.6 million. The balance sheet shows total assets of $1.92 billion against total liabilities of $2.10 billion, leaving shareholders’ equity at negative $181.1 million. Research and development expense was $91.0 million, inventory net was $83.9 million, and inventory decreased by $2.0 million during the quarter. Diluted earnings per share came in at negative $0.85 on 131.3 million weighted average diluted shares outstanding. The company also disclosed $5.6 million in capital expenditure for property, plant, and equipment, a figure that looks almost quaint next to the R&D burn.

Guardant’s official site carries a product image of its Guardant360 CDx test, confirming the offering’s FDA-cleared status as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, a pairing announced in the issuer’s newsroom. The image is the clearest visual evidence the company has provided recently, while the last substantive press release-dated May 7, 2026-simply restated the March 31 results and offered no new financial guidance. The SEC filings index for Guardant Health lists eight filings so far in June, including an 8-K on June 18 and six Form 4s filed between June 16 and June 17, a flurry that looks less like operational updates and more like a management team practising its exit pace.

The company’s product pipeline and commercial traction remain anchored in companion diagnostics and data services, but the filing evidence shows widening losses, negative equity, and cash burn that persists despite a strong balance sheet. The FDA approval for use with HERNEXEOS adds regulatory credibility but does not yet translate into a clear path to GAAP profitability. Investors are left parsing Form 4s and 10-Qs for clues about whether the cash is being husbanded for a clinical or commercial inflection or simply parked while the board decides what to do next. The next material catalyst would be a quarter in which operating cash flow turns positive or a filing that discloses concrete revenue milestones tied to the companion diagnostic pipeline rather than general-purpose oncology data services. Until then, the stock trades on narrative rather than numbers, and the numbers currently read like a cautionary tale wrapped in a biotech bow.